Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes

Mary Anne Cotter, Alison Margaret Jack, Norman E Cameron

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Elevated protein kinase C activity has been linked to the vascular and neural complications of diabetes. The aim of the present study was to examine the involvement of the beta-isoform of protein kinase C in abnormalities of neuronal function, neural tissue perfusion and endothelium-dependent vasodilation in diabetes, by treatment with the selective inhibitor LY333531 (10 mg (.) kg(-1) (.) day(-1)). Diabetes was induced in rats by streptozotocin; the duration of diabetes was 8 weeks. Nerve conduction velocity was monitored, and responses to noxious mechanical and thermal stimuli were estimated by the Randall-Sellito and Hargreaves tests respectively. Sciatic nerve and superior cervical ganglion blood flow were measured by microelectrode polarography and hydrogen clearance. Vascular responses were examined using the in vitro mesenteric bed preparation. An 8-week period of diabetes caused deficits in sciatic motor (20%) and saphenous nerve sensory (16%) conduction velocity, which were reversed by LY333531. Diabetic rats had mechanical and thermal hyperalgesia. LY333531 treatment did not affect mechanical thresholds, but corrected thermal hyperalgesia. Sciatic nerve and superior cervical ganglion blood flow were both reduced by 50% by diabetes; this was almost completely corrected by 2 weeks of LY333531 treatment. Diabetes caused a 32% reduction in vasodilation of the mesenteric vascular bed in response to acetylcholine, mediated by nitric oxide and endothelium-derived hyperpolarizing factor. When the former was abolished during nitric oxide synthase inhibition, an 80% diabetic deficit in the remaining relaxation was noted. LY333531 treatment attenuated the development of these defects by 64% and 53% respectively. Thus protein kinase Cbeta contributes to the neural and vascular complications of experimental diabetes; LY333531 is a candidate for further study in clinical trials of diabetic neuropathy and vasculopathy.

Original languageEnglish
Pages (from-to)311-321
Number of pages10
JournalClinical Science
Volume103
Issue number3
Publication statusPublished - 2002

Keywords

  • blood flow
  • diabetic rat
  • endothelium-dependent relaxation
  • endothelium-derived hyperpolarizing factor
  • nerve conduction
  • neuropathy
  • nitric oxide
  • pain
  • protein kinase C
  • sensory thresholds
  • ALDOSE REDUCTASE INHIBITION
  • NITRIC-OXIDE SYNTHASE
  • NERVE-CONDUCTION
  • ENDOTHELIAL DYSFUNCTION
  • CORPUS CAVERNOSUM
  • POLYOL PATHWAY
  • BLOOD-FLOW
  • NEUROPATHY
  • RELAXATION
  • HYPERALGESIA

Cite this

Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. / Cotter, Mary Anne; Jack, Alison Margaret; Cameron, Norman E.

In: Clinical Science, Vol. 103, No. 3, 2002, p. 311-321.

Research output: Contribution to journalArticle

Cotter, Mary Anne ; Jack, Alison Margaret ; Cameron, Norman E. / Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. In: Clinical Science. 2002 ; Vol. 103, No. 3. pp. 311-321.
@article{a2c760b89bf04540b3136a1937f44047,
title = "Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes",
abstract = "Elevated protein kinase C activity has been linked to the vascular and neural complications of diabetes. The aim of the present study was to examine the involvement of the beta-isoform of protein kinase C in abnormalities of neuronal function, neural tissue perfusion and endothelium-dependent vasodilation in diabetes, by treatment with the selective inhibitor LY333531 (10 mg (.) kg(-1) (.) day(-1)). Diabetes was induced in rats by streptozotocin; the duration of diabetes was 8 weeks. Nerve conduction velocity was monitored, and responses to noxious mechanical and thermal stimuli were estimated by the Randall-Sellito and Hargreaves tests respectively. Sciatic nerve and superior cervical ganglion blood flow were measured by microelectrode polarography and hydrogen clearance. Vascular responses were examined using the in vitro mesenteric bed preparation. An 8-week period of diabetes caused deficits in sciatic motor (20{\%}) and saphenous nerve sensory (16{\%}) conduction velocity, which were reversed by LY333531. Diabetic rats had mechanical and thermal hyperalgesia. LY333531 treatment did not affect mechanical thresholds, but corrected thermal hyperalgesia. Sciatic nerve and superior cervical ganglion blood flow were both reduced by 50{\%} by diabetes; this was almost completely corrected by 2 weeks of LY333531 treatment. Diabetes caused a 32{\%} reduction in vasodilation of the mesenteric vascular bed in response to acetylcholine, mediated by nitric oxide and endothelium-derived hyperpolarizing factor. When the former was abolished during nitric oxide synthase inhibition, an 80{\%} diabetic deficit in the remaining relaxation was noted. LY333531 treatment attenuated the development of these defects by 64{\%} and 53{\%} respectively. Thus protein kinase Cbeta contributes to the neural and vascular complications of experimental diabetes; LY333531 is a candidate for further study in clinical trials of diabetic neuropathy and vasculopathy.",
keywords = "blood flow, diabetic rat, endothelium-dependent relaxation, endothelium-derived hyperpolarizing factor, nerve conduction, neuropathy, nitric oxide, pain, protein kinase C, sensory thresholds, ALDOSE REDUCTASE INHIBITION, NITRIC-OXIDE SYNTHASE, NERVE-CONDUCTION, ENDOTHELIAL DYSFUNCTION, CORPUS CAVERNOSUM, POLYOL PATHWAY, BLOOD-FLOW, NEUROPATHY, RELAXATION, HYPERALGESIA",
author = "Cotter, {Mary Anne} and Jack, {Alison Margaret} and Cameron, {Norman E}",
year = "2002",
language = "English",
volume = "103",
pages = "311--321",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes

AU - Cotter, Mary Anne

AU - Jack, Alison Margaret

AU - Cameron, Norman E

PY - 2002

Y1 - 2002

N2 - Elevated protein kinase C activity has been linked to the vascular and neural complications of diabetes. The aim of the present study was to examine the involvement of the beta-isoform of protein kinase C in abnormalities of neuronal function, neural tissue perfusion and endothelium-dependent vasodilation in diabetes, by treatment with the selective inhibitor LY333531 (10 mg (.) kg(-1) (.) day(-1)). Diabetes was induced in rats by streptozotocin; the duration of diabetes was 8 weeks. Nerve conduction velocity was monitored, and responses to noxious mechanical and thermal stimuli were estimated by the Randall-Sellito and Hargreaves tests respectively. Sciatic nerve and superior cervical ganglion blood flow were measured by microelectrode polarography and hydrogen clearance. Vascular responses were examined using the in vitro mesenteric bed preparation. An 8-week period of diabetes caused deficits in sciatic motor (20%) and saphenous nerve sensory (16%) conduction velocity, which were reversed by LY333531. Diabetic rats had mechanical and thermal hyperalgesia. LY333531 treatment did not affect mechanical thresholds, but corrected thermal hyperalgesia. Sciatic nerve and superior cervical ganglion blood flow were both reduced by 50% by diabetes; this was almost completely corrected by 2 weeks of LY333531 treatment. Diabetes caused a 32% reduction in vasodilation of the mesenteric vascular bed in response to acetylcholine, mediated by nitric oxide and endothelium-derived hyperpolarizing factor. When the former was abolished during nitric oxide synthase inhibition, an 80% diabetic deficit in the remaining relaxation was noted. LY333531 treatment attenuated the development of these defects by 64% and 53% respectively. Thus protein kinase Cbeta contributes to the neural and vascular complications of experimental diabetes; LY333531 is a candidate for further study in clinical trials of diabetic neuropathy and vasculopathy.

AB - Elevated protein kinase C activity has been linked to the vascular and neural complications of diabetes. The aim of the present study was to examine the involvement of the beta-isoform of protein kinase C in abnormalities of neuronal function, neural tissue perfusion and endothelium-dependent vasodilation in diabetes, by treatment with the selective inhibitor LY333531 (10 mg (.) kg(-1) (.) day(-1)). Diabetes was induced in rats by streptozotocin; the duration of diabetes was 8 weeks. Nerve conduction velocity was monitored, and responses to noxious mechanical and thermal stimuli were estimated by the Randall-Sellito and Hargreaves tests respectively. Sciatic nerve and superior cervical ganglion blood flow were measured by microelectrode polarography and hydrogen clearance. Vascular responses were examined using the in vitro mesenteric bed preparation. An 8-week period of diabetes caused deficits in sciatic motor (20%) and saphenous nerve sensory (16%) conduction velocity, which were reversed by LY333531. Diabetic rats had mechanical and thermal hyperalgesia. LY333531 treatment did not affect mechanical thresholds, but corrected thermal hyperalgesia. Sciatic nerve and superior cervical ganglion blood flow were both reduced by 50% by diabetes; this was almost completely corrected by 2 weeks of LY333531 treatment. Diabetes caused a 32% reduction in vasodilation of the mesenteric vascular bed in response to acetylcholine, mediated by nitric oxide and endothelium-derived hyperpolarizing factor. When the former was abolished during nitric oxide synthase inhibition, an 80% diabetic deficit in the remaining relaxation was noted. LY333531 treatment attenuated the development of these defects by 64% and 53% respectively. Thus protein kinase Cbeta contributes to the neural and vascular complications of experimental diabetes; LY333531 is a candidate for further study in clinical trials of diabetic neuropathy and vasculopathy.

KW - blood flow

KW - diabetic rat

KW - endothelium-dependent relaxation

KW - endothelium-derived hyperpolarizing factor

KW - nerve conduction

KW - neuropathy

KW - nitric oxide

KW - pain

KW - protein kinase C

KW - sensory thresholds

KW - ALDOSE REDUCTASE INHIBITION

KW - NITRIC-OXIDE SYNTHASE

KW - NERVE-CONDUCTION

KW - ENDOTHELIAL DYSFUNCTION

KW - CORPUS CAVERNOSUM

KW - POLYOL PATHWAY

KW - BLOOD-FLOW

KW - NEUROPATHY

KW - RELAXATION

KW - HYPERALGESIA

M3 - Article

VL - 103

SP - 311

EP - 321

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 3

ER -